Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High dose PPI with chemotherapy in metastatic breast cancer
NCT01069081Phase 2Completed
- Sponsor
- Fudan University
- Start
- Aug 2009
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of esomeprazole in breast cancer (3 arms), sponsored by Fudan University. Primary endpoint: Time to progression at 6 weeks. Started Aug 2009; status: completed.
02
Drugs
esomeprazole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01069081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069081.